UK & ROI
Consumer
Search
Product search
Practitioner home > Our Products > Biofinity® family

Biofinity family

Family products

Biofinity Energys® Monthly Replacement Short-sightedness/Long-sightedness*
Biofinity® & Biofinity® XR Monthly Replacement Short-sightedness/Long-sightedness*
Biofinity® toric & Biofinity® XR toric Monthly Replacement Astigmatism†
Biofinity® multifocal Monthly Replacement Presbyopia‡
Biofinity® toric multifocal Monthly Replacement ASTIGMATISM† PRESBYOPIA‡

Biofinity® contact lenses are trusted by eye care professionals and loved by wearers worldwide.§◊1,2 With world-class design and the widest silicone hydrogel prescription range, virtually all of your patients can enjoy great vision, incredible comfort and a healthy lens-wearing experience.¶**††3,4,5,6

 

Suitable for overnight wear.7 Available in sphere, toric, multifocal and toric multifocal, with extended ranges offered in sphere and toric options.

Packaging images for illustration purposes only.

*With myopia (short-sightedness) or hyperopia (long-sightedness).
†With myopia or hyperopia with astigmatism.
‡ With myopia, hyperopia or emmetropia with presbyopia.
§ On average, 85% strongly/somewhat agree.
◊ On average, 84% strongly/somewhat agree.
¶ Based on Rx option combinations (sphere, cylinder, axis & add) manufactured, across all soft lenses in sphere, toric & multifocal (including made to order), in SiHy from 4 main manufacturers. Includes one-day, 2 weekly, and monthly replacement contact lenses. Cosmetic & Photochromatic contact lenses not included. Multiple base curve variants not included.
** On average, 83% strongly/somewhat agree.
†† Applies only to patients wearing Biofinity® family contact lenses.
 

References: 
1. CVI data on file 2021. Decision Analyst online survey of 376 Biofinity® prescribing ECPs in USA, Japan, Germany, France and Spain.
2. CVI data on file 2021. Decision Analyst online survey of 1,027 Biofinity® wearers aged 16-65 years in USA, Japan, Germany, France and Spain.
3. CVI data on file, 2023. Industry reports and internal estimates based on Tyler's Quarterly, 12/2022.
4. CVI data on file 2021. Decision Analyst online survey of 376 Biofinity® prescribing ECPs in USA, Japan, Germany, France and Spain.
5. CVI Data on file, 2024. CVI data on file, 2023; Based on global product sales and internal estimates of products using Aquaform® Technology over 12 months in 2023.
6. CVI data on file, 2024.
7. A.M. Moezzi, et al. Overnight Corneal Swelling, CLAO; 32(6): 277–280.

SA13061/ APP135588